The graft-vs.-leukemia effect : implications for post-marrow transplant antileukemia treatment : Bone marrow transplantationSOSMAN, J. A; SONDEL, P. M.The American journal of pediatric hematology/oncology. 1993, Vol 15, Num 2, pp 185-195, issn 0192-8562Article

Specific recognition of human leukemic cells by allogenic T cells : II, Evidence for HLA-D restricted determinants on leukemic cells that are crossreactive with determinants present on unrelated nonleukemic cellsSOSMAN, J. A; OETTEL, K. R; SMITH, S. D et al.Blood. 1990, Vol 75, Num 10, pp 2005-2016, issn 0006-4971, 12 p.Article

Antigen-specific recognition of autologous leukemia cells and allogeneic class-I MHC antigens by IL-2-activated cytotoxic T cells from a patient with acute T-cell leukemiaFISCH, P; WEIL-HILLMAN, G; UPPENKAMP, M et al.Blood. 1989, Vol 74, Num 1, pp 343-353, issn 0006-4971Article

Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancerSONDEL, P. M; KOHLER, P. C; HANK, J. A et al.Cancer research (Baltimore). 1988, Vol 48, Num 9, pp 2561-2567, issn 0008-5472Article

A phase IA/IB trial of anti-CD3 murine monoclonal antibody plus low-dose continuous-infusion interleukin-2 in advanced cancer patientsSOSMAN, J. A; KEFER, C; FISHER, R. I et al.Journal of immunotherapy with emphasis on tumor immunology. 1995, Vol 17, Num 3, pp 171-180, issn 1067-5582Article

A phase II study of the continuous intravenous infusion of interleukin-6 for metastatic renal cell carcinomaWEISS, G. R; MARGOLIN, K. A; FISHER, R. I et al.Journal of immunotherapy with emphasis on tumor immunology. 1995, Vol 18, Num 1, pp 52-56, issn 1067-5582Article

A phase I trial of interleukin 3 (IL-3) pre-bone marrow harvest with granulocyte-macrophage colony-stimulating factor (GM-CSF) post-stem cell infusion in patients with solid tumours receiving high-dose combination chemotherapySOSMAN, J. A; STIFF, P. J; FISHER, S. G et al.Bone marrow transplantation (Basingstoke). 1995, Vol 16, Num 5, pp 655-661, issn 0268-3369Article

Allogeneic T-cell clones able to selectively destroy Philadelphia chromosome-bearing (Ph¹⁺) human leukemia lines can also recognize Ph^1- cells from the same patientOETTEL, K. R; WESLY, O. H; ALBERTINI, M. R et al.Blood. 1994, Vol 83, Num 11, pp 3390-3402, issn 0006-4971Article

Daily subcutaneous ultra-low-dose interleukin 2 with daily low-dose interferon-α in patients with advanced renal cell carcinomaCLARK, J. I; GAYNOR, E. R; MARTONE, B et al.Clinical cancer research. 1999, Vol 5, Num 9, pp 2374-2380, issn 1078-0432Article

Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients : Reversible dose-limiting neurological toxicitySOSMAN, J. A; ARONSON, F. R; MIER, J et al.Clinical cancer research. 1997, Vol 3, Num 1, pp 39-46, issn 1078-0432Article

Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma : clinical and immunologic effectsSOSMAN, J. A; WEISS, G. R; ERNEST, M. L et al.Journal of clinical oncology. 1993, Vol 11, Num 8, pp 1496-1505, issn 0732-183XArticle

Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinomaATKINS, M. B; SPARANO, J; SOSMAN, J. A et al.Journal of clinical oncology. 1993, Vol 11, Num 4, pp 661-670, issn 0732-183XArticle

Addition of interleukin-2 in vitro augments detection of lymphokine-activated killer activity generated in vivoHANK, J. A; WEIL-HILLMAN, G; SURFUS, J. E et al.Cancer immunology and immunotherapy. 1990, Vol 31, Num 1, pp 53-59, issn 0340-7004, 7 p.Article

Repetitive weekly cycles of interleukin-2. II: Clinical and immunologic effects of dose, schedule, and addition of indomethacinSOSMAN, J. A; KOHLER, P. C; HANK, J. A et al.Journal of the National Cancer Institute. 1988, Vol 80, Num 18, pp 1451-1461, issn 0027-8874Article

A multi-institutional phase II trial of a novel inpatient schedule of continuous interleukin-2 with interferon α-2b in advanced renal cell carcinoma: major durable responses in a less highly selected patient populationCLARK, J. I; KUZEL, T. M; LESTINGI, T. M et al.Annals of oncology. 2002, Vol 13, Num 4, pp 606-613, issn 0923-7534Article

Phase II trial of biochemotherapy with interferon α, dacarbazine, cisplatin and tamoxifen in metastatic melanoma : a southwest oncology group trialMARGOLIN, K. A; LIU, P. Y; WEISS, G. R et al.Journal of cancer research and clinical oncology. 1999, Vol 125, Num 5, pp 292-296, issn 0171-5216Article

Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-y productionLEONARD, J. P; SHERMAN, M. L; FISHER, G. L et al.Blood. 1997, Vol 90, Num 7, pp 2541-2548, issn 0006-4971Article

Induction of human cytotoxic T lymphocytes specific for prostate-specific antigenXUE, B.-H; ZHANG, Y; SOSMAN, J. A et al.The Prostate. 1997, Vol 30, Num 2, pp 73-78, issn 0270-4137Article

Evidence for eosinophil activation in cancer patients receiving recombinant interleukin-4: effects of interleukin-4 alone and following interleukin-2 administrationSOSMAN, J. A; BARTEMES, K; OFFORD, K. P et al.Clinical cancer research. 1995, Vol 1, Num 8, pp 805-812, issn 1078-0432Article

Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide, and autologous bone marrow rescue : high response rate for refractory ovarian carcinomaSTIFF, P. J; MCKENZIE, R. S; ALBERTS, D. S et al.Journal of clinical oncology. 1994, Vol 12, Num 1, pp 176-183, issn 0732-183XArticle

Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast cancer patients undergoing high-dose chemotherapy : Expansion of immune effectors within the stem-cell graft and post-stem-cell infusionSOSMAN, J. A; STIFF, P; CHEN, Y et al.Journal of clinical oncology. 2001, Vol 19, Num 3, pp 634-644, issn 0732-183XArticle

Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma : A southwest oncology group studyMARGOLIN, K. A; LIU, P.-Y; FLAHERTY, L. E et al.Journal of clinical oncology. 1998, Vol 16, Num 2, pp 664-669, issn 0732-183XArticle

A phase II trial of piroxantrone in disseminated malignant melanomaSOSMAN, J. A; FLAHERTY, L. E; LIU, P. Y et al.Investigational new drugs. 1995, Vol 13, Num 1, pp 83-87, issn 0167-6997Article

Activation of human T cells obtained pre- and post-interleukin-2 (IL-2) therapy by anti-CD3 monoclonal antibody plus IL-2 : implications for combined in vivo treatmentWEIL-HILLMAN, G; SCHELL, K; SEGAL, D. M et al.Journal of immunotherapy. 1991, Vol 10, Num 4, pp 267-277, issn 1053-8550Article

γ/δ T cell clones and natural killer cell clones mediate distinct patterns of non-major histocompatibility complex-restricted cytolysisFISCH, P; MALKOVSKY, M; BRAAKMAN, E et al.The Journal of experimental medicine. 1990, Vol 171, Num 5, pp 1567-1579, issn 0022-1007, 13 p.Article